Glass M, Northup J K
Section on Signal Transduction, National Institutes of Health, National Institute on Deafness and Other Communication Disorders, Rockville, Maryland 20850, USA.
Mol Pharmacol. 1999 Dec;56(6):1362-9. doi: 10.1124/mol.56.6.1362.
We have examined the ligand regulation and G protein selectivity of the human cannabinoid CB(1) and CB(2) receptors by an in situ reconstitution technique directly measuring G protein activation. Membranes from Spodoptera frugiperda cells expressing CB(1) and CB(2) receptors were chaotrope extracted to denature endogenous GTP-binding proteins. The ability of the receptors to catalyze the GDP-GTP exchange of each G protein was then examined with purified bovine brain G(i) and G(o). Activation of CB(1) receptors produced a high-affinity saturable interaction for both G(i) and G(o). Agonist stimulation of CB(2) receptors also resulted in a high-affinity saturable interaction with G(i). In contrast, CB(2) receptors did not interact efficiently with G(o). G protein activation was then examined with a diverse group of ligands. For the interaction of CB(2) receptors with G(i), HU210 was the only compound tested that demonstrated maximal activation. In contrast, WIN55,212 (64%), anandamide (42%), and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (44%) all initiated submaximal levels of G protein activation. For CB(1) receptor-catalyzed activation of G(i), HU210, WIN55,212, and anandamide all elicited maximal activation, whereas Delta(9)-THC (56 +/- 6%) caused only partial G(i) activation. In contrast, only HU210 effected maximal CB(1) stimulation of G(o), with anandamide, WIN55, 212, and Delta(9)-THC all stimulating between 60 and 75% compared with HU210. These data demonstrate that different agonists induce different conformations of the CB(1) receptor, which in turn can distinguish between different G proteins. Our data thus demonstrate agonist-selective G protein signaling by the CB(1) receptor and suggest that therapeutic agents may be designed to regulate individual G protein-signaling pathways selectively.
我们通过直接测量G蛋白激活的原位重组技术,研究了人大麻素CB(1)和CB(2)受体的配体调节及G蛋白选择性。从表达CB(1)和CB(2)受体的草地贪夜蛾细胞中提取的膜,经离液剂处理以变性内源性GTP结合蛋白。然后用纯化的牛脑G(i)和G(o)检测受体催化各G蛋白GDP-GTP交换的能力。CB(1)受体的激活对G(i)和G(o)均产生高亲和力的饱和相互作用。CB(2)受体的激动剂刺激也导致与G(i)的高亲和力饱和相互作用。相比之下,CB(2)受体与G(o)的相互作用效率不高。然后用一组不同的配体检测G蛋白激活情况。对于CB(2)受体与G(i)的相互作用,HU210是所测试的唯一显示最大激活的化合物。相比之下,WIN55,212(64%)、花生四烯乙醇胺(42%)和Δ⁹-四氢大麻酚(Δ⁹-THC)(44%)均引发次最大水平的G蛋白激活。对于CB(1)受体催化的G(i)激活,HU210、WIN55,212和花生四烯乙醇胺均引发最大激活,而Δ⁹-THC(56±6%)仅引起部分G(i)激活。相比之下,只有HU210能使CB(1)对G(o)产生最大刺激,花生四烯乙醇胺、WIN55,212和Δ⁹-THC与HU210相比,刺激程度均在60%至75%之间。这些数据表明,不同的激动剂可诱导CB(1)受体产生不同的构象,进而能够区分不同的G蛋白。因此,我们的数据证明了CB(1)受体存在激动剂选择性的G蛋白信号传导,并表明可以设计治疗药物来选择性调节各个G蛋白信号传导途径。